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Hedgehog pathway mutations in T-cell acute 
lymphoblastic leukemia
Hedgehog signaling plays an important role in both
embryonic pattern formation and in proliferation, survival
and differentiation of adult tissues, including T cells.1,2 We
report here the presence of rare acquired mutations in
genes encoding components of the Hedgehog signaling
pathway in T-cell acute lymphoblastic leukemia (T-ALL). In
the 4 cases in which a detailed analysis was possible, we
document the mutations in both neoplastic and normal
hematopoietic cells, but not in epithelial cells. Functional
analysis confirms the gain-of-function properties of two
truncated smoothened (SMO) mutations identified in this
study.
In mammalian cells, Hedgehog signaling involves three
different ligands, Sonic Hedgehog (SHH), Indian Hedgehog
(IHH) or Desert Hedgehog (DHH), each with different spa-
tial and temporal distribution pattern. Hedgehog ligand
binds to and inhibits its receptor patched 1 (PTCH1) or
patched 2 (PTCH2), two multipass transmembrane pro-
teins, and thereby results in release, accumulation and acti-
vation of SMO in the primary cilium. This in turn activates
GLI transcription factors (GLI1, GLI2, and GLI3), which
translocate into the nucleus and act as transcriptional acti-
vators or repressors. Previous studies have shown that
mutations in PTCH1 are responsible for the majority of
nevoid basal cell carcinoma syndrome and basal cell carci-
noma cases, and also mutations of SMO and SUFU have
been identified.3
Several lines of evidence suggest that the Hedgehog
pathway is important for normal T-cell development. 
In vivo studies in fetal4 and adult5 thymus have shown that
Smo-induced signals are essential for homeostasis, differen-
tiation and proliferation of early T thymocytes, especially
at the DN1-DN2 stage. Likewise, Shh ligand is important
for differentiation and proliferation of more immature T
cells (at the DN stage) but is also important for DN to DP
transition, as well as influencing the CD4/CD8 ratio.2
Finally, Ihh promotes T-cell differentiation before pre-TCR
signal transduction, but acts as negative T-cell regulator in
later developmental stages.4 
Despite the frequent mutation of the Hedgehog pathway
in solid tumors, mutations in hematologic malignancies
have not yet been described. We recently performed exome
sequencing in T-ALL and identified several single
nucleotide variants (SNVs) in genes encoding members of
the Hedgehog pathway.6 As these SNVs were also detected
in DNA from remission, we initially believed that these
SNVs were rare polymorphisms. However, upon more
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Table 1. Mutations identified in different Hedgehog components in T-ALL patients. 
Patient Gene Transcript Diagnosis DNA Germline DNA Amino acid Protein Other characteristics
number nucleotide nucleotide change affecting
change sequence score
TLE41p SMO NM005631 C2176T wild type R726* Damaging Male, 16 years, relapsed,
MLL fusion,
NUP214-ABL1,
NOTCH1 L2429fs,
IL7R I244
delinsNDCS
TLE67 SMO NM005631 C2287T wild type R763* Damaging Male, 14 years, 
complete remission,
TAL1,
NUP214-ABL1,
NOTCH1 F1606LGEIP,
TLE40 GLI1 NM005269 C1613T wild type S538F Damaging Male, 38 years, 
complete remission
TLE44 GLI3 NM000168 G2179A wild type G727R Damaging Female, 29 years, relapsed,
TLX3, 
NOTCH1 S2467fs, JAK3 M511I
TLE61p PTCH1 NM000264 G1306A G1306A D436N Benign Male, 13 years, complete 
remission, RPL10 R98S
TLE59p GLI3 NM000168 G3001A G3001A G1001S Benign Male, 7 years, allotransplant,
TLX3, NOTCH1 L1678P,
WT1 R369G
TLE70 PTCH1 NM000264 C2173T NA P725S Benign PTPN2 deletion
TLE37 PTCH2 NM003738 C2711T NA P904L Damaging Male, 37 years, relapsed, 
PTPRC D433N
TBR1 GLI3 NM000168 G1097T NA R366L Damaging Male, 35 years, IL7R F250V253
delinsPLGE
Sequence variations in Hedgehog components were identified in 9 of 50 T-ALL samples. All variations were heterozygous. Germline DNA was obtained from buccal swabs
(n=4), skin (n=1), or liver (n=1) for 6 cases. The PTCH1-D436N variation detected in case TLE61 is known as a SNP (rs142274954). The protein score reflects the prediction
by 3 different algorithms (Condel, SIFT, Polyphen): the score was considered to be damaging when at least 2 of the 3 predictions were damaging. Nucleotide counting started
at the A from the start codon of the indicated transcript. NA: not available; fs: frameshift mutations; ppediatric patient.
detailed analysis, we confirmed that these SNVs were not
present in DNA extracted from non-hematopoietic tissues,
indicating that these variants were only present in the
leukemia cells and in normal hematopoietic cells.
We identified SNVs in different genes of the Hedgehog
pathway in 9 T-ALL samples (Table 1). Four of these 9
sequence variations were confirmed to be somatic muta-
tions, based on the analysis of available germline DNA of
the same individuals (Figure 1). Remarkably, these four
somatic mutations were still detected in DNA extracted
from blood cells at time of remission, while other driver
mutations (NOTCH1, etc.) detected in these samples were,
as expected, absent at remission (Table 1). This finding sug-
gests that the Hedgehog pathway mutations were acquired
as de novo mutations in the hematopoietic compartment,
potentially early in life. A similar finding was recently
reported as one of the two possible explanations for TP53
mutations in hypodiploid ALL.7
Of the five other variations detected in Hedgehog com-
ponents, two were shown to be present in germline DNA,
indicating that these were likely rare polymorphisms, and
these variations were also predicted not to alter protein
structure. The other 3 sequence variations, identified in T-
ALL samples for which no germline DNA was available,
could still represent true somatic mutations, and predic-
tions indicate a damaging effect for two of these variations
(Table 1). 
Two of the detected acquired mutations were truncating
mutations of SMO (R726* and R763*), located in the C-ter-
minus of the protein. This C-terminus contains several argi-
nine clusters that are important in blocking the SMO cell
surface expression and inhibit the conformational switch of
SMO to its active form.8 The two other acquired mutations
are a GLI1 point mutation (S538F) and a GLI3 point muta-
tion (G727R), which are both located downstream of the
zinc finger domain and predicted to be damaging for the
protein. Moreover, the GLI3-G727R mutation was previ-
ously identified in individuals with postaxial polydactyly
(PAP),9 a disease known to be caused by GLI3 defects, sup-
porting the view that the GLI3-G727R mutation identified
in T-ALL also affects GLI3 function. 
To confirm the oncogenic properties of SMO-R763*, we
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Figure 1. Sanger sequencing profiles
of T-ALL cases with Hedgehog pathway
mutations. Sanger sequencing in 6 T-
ALL cases on DNA from diagnosis and
germline DNA confirmed that 4 of the
6 Hedgehog pathway mutations were
somatic mutations. 
Figure 2. Identification of acquired mutations in the Hedgehog
pathway. (A) Functional analysis of the SMO-R763* mutant was
performed in HEK293T cells. The proliferation of the cells was
measured 4, 5 and 6 days after transfection (cell numbers at day 4
are shown). The experiment was repeated three times and each
sample was analyzed in triplicate. The total amount of DNA used
for the transfections was constant. WT: wild type. (B) Frequency of
CD4CD8 double negative (DN) population in the thymus of Balb/C
mice transplanted with hematopoietic progenitor cells expressing
various SMO mutants.  
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used the HEK293T cell system previously reported by
Barnes et al. in a study of PTCH1 mutants.10 We reasoned
that if the SMO-R763* mutant identified in our study was
an activating mutant, we would be able to increase the pro-
liferation of HEK 293T cells by expressing this mutant, and
this effect on proliferation would be insensitive to PTCH1
inhibition. As control we used the SMO-wild type and a
known activating mutant SMO-W539L.11 To distinguish
between the effects caused by the overexpression and by
the overactivation of SMO, we co-transfected each SMO
construct with a PTCH1-wild-type construct, with the aim
of testing if PTCH1 could still inhibit the SMO mutants.
HEK 293T cells transfected with wild-type SMO had a
clear proliferation advantage that could be partially inhibit-
ed by co-expression of PTCH1 (Figure 2A). Similarly,
expression of the SMO-W539L or SMO R763* resulted in
increased proliferation of the 293T cells, but these SMO
mutants could not be inhibited by PTCH1 co-expression
(Figure 2A). These data demonstrate that the SMO-R763*
mutation is a typical SMO-activating mutation that is
insensitive to PTCH1 inhibition and is capable of stimulat-
ing cell proliferation.
We next evaluated the capacity of these two SMO
mutants to activate the Hedgehog pathway in vivo.
Hematopoietic progenitors were transduced with the
SMO-R763* or the SMO-R726* mutants, or with controls
(empty MSCV-GFP vector, SMO-wild type vector, or the
known activating mutant SMO-W539L). Transduced pro-
genitor cells were injected into irradiated Balb/c mice. Flow
cytometric analysis of these mice revealed an increase of
CD4CD8 double negative cells in the thymus expressing
the 3 SMO mutants (GFP positive cells) compared to GFP
negative cells from the same mice or cells obtained from
MSCV-GFP or SMO-wt mice (Figure 2B). Moreover, 11 of
13 mice expressing the SMO mutants showed enlarged
lymph nodes with a major T-cell infiltration (Figure 2B).
Nevertheless, none of these mice developed leukemia
implying that activation of the hedgehog pathway is not
sufficient to cause leukemia. Taken together, these data
clearly demonstrate that SMO-R763* and SMO-R726*
mutants can block the T-cell development in vivo in a simi-
lar way as the mutant SMO-W539L that activates the
Hedgehog pathway.
T-ALL is a genetically complex leukemia where multiple
genomic aberrations co-operate to transform normal T-cell
precursors to fully malignant thymocytes. Here we provide
evidence that also components of the Hedgehog pathway
can be mutated in T-ALL. As a direct proof of activation of
the Hedgehog pathway in T-ALL, we identified acquired
mutations in 4 T-ALL samples (SMO-R726*, SMO-R763*,
GLI1-S538F andGLI3-G727R). In 2 additional T-ALL cases
we identified variations in PTCH2 and GLI3 that are pre-
dicted to affect these proteins, but for which we do not
have evidence that these sequence variations are acquired,
as no germline DNA was available for these patients.
Remarkably, and in contrast to other somatic mutations
detected in the T-ALL samples, the somatic mutations in
SMO, GLI1 and GLI3 were still present at high frequency
at time of remission. This observation can potentially be
explained by the de novo acquisition of these mutations
early in life in the hematopoietic compartment. Similar
findings had previously been reported for a set of TP53
mutations in ALL, as the same mutations were identified in
non-tumor hematopoietic cells in remission.7 It would be
interesting to explore this further in future studies. It is also
remarkable that this was observed for all 4 somatic muta-
tions in SMO, GLI1 and GLI3, which seems to indicate that
such mutations in the Hedgehog pathway are more delete-
rious early on than during adult hematopoiesis. This is in
agreement with previous work illustrating an important
role for Gli3 in the control of T-cell differentiation during
fetal development and not during adult development.12
Taken together, our data indicate that the Hedgehog
pathway can be activated in a subset of T-ALL through
mutations in critical proteins of the pathway. These data
contrast previous reports that showed that the Hedgehog
pathway was dispensable for a NOTCH1-driven T-ALL
mouse model.13 These different conclusions may be
explained by the differences between the mouse model and
the human disease. NOTCH1 is a very strong oncogene in
mouse models (especially when it is over-expressed), while
the human leukemias have lower NOTCH1 activation and
still require additional mutations for their further evolution
towards an aggressive leukemia. In addition, we have to
take into account that we only detected a low frequency of
Hedgehog pathway mutations in T-ALL. Also, high expres-
sion of Hedgehog pathway components and sensitivity to
Hedgehog antagonists in mouse and T-LBL patients as well
as B-ALL cell lines further illustrate a role for the Hedgehog
pathway in ALL.14,15 Our data identify the Hedgehog path-
way as an oncogenic pathway in a subset of T-ALL cases
and as a potential target for therapy in T-ALL. Additional
data are required to determine the exact origin of these
mutations and to determine if treatment with Hedgehog
pathway inhibitors could be beneficial in these cases.
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